A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

NCT ID: NCT06200376

Last Updated: 2024-01-11

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-09-28
• Study Completion Date: 2024-12-31

Brief Summary

This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intraperitoneal administration of T3011 at different doses in the treatment of malignant ascites induced by advanced colorectal cancer.

Conditions

Malignant Ascites

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

T3011

Group Type: EXPERIMENTAL

T3011

Intervention Type: DRUG

T3011 will be administered intraperitoneally twice a week.

Interventions

T3011

T3011 will be administered intraperitoneally twice a week.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female age ≥ 18 years and ≤ 75 years at the time of informed consent.

2. Histologically or cytologically confirmed advanced unresectable or metastatic colorectal cancer;

3. Anticipated life expectancy ≥3 months

4. Associated with medium amount of malignant ascites (defined as the amount of ascites ≥3cm by B ultrasonography in lying position accompanied by clinical symptomes like abdonimal distension and cytology tests possitive for tumor in ascites); No paracentesis performed with 28 days before first dosing; and the ascites can not be controlled by SOC according to PI judgement.

5. ECOG performance status 0-2 (including threshold);

6. Weight ≥40kg

7. Hematology:

• White blood cell (WBC) ≥ 3.0×10^9/L;
• Neutrophil (ANC) ≥ 1.5×10^9/L;
• Platelet (PLT) ≥ 75×10^9/L;
• Hemoglobin (Hb) ≥ 8.0g/dL

8. Hepatic and renal function:

• Total bilirubin ≤ 1.5 × ULN;
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 × ULN for patient without liver metastasis, ≤ 5 × ULN for patients with liver metastasis;
• Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL/min as determined by the Cockcroft-Gault equation;
• Abumin≥30 g/L

9. Coagulation:

• INR≤1.5 x ULN;
• APTT≤1.5 x ULN;

10. For women of childbearing potential (WCBP), serum pregnancy test should be negative within 14 days before dosing. WCBP patients, as well as male patients with partners of WCBP, should consent to use at least one medically approved contraceptive method (e.g. surgical sterilization, oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicides) during the study and for at least 6 months after the last dosing;

11. Willingness to attend this study, to sign informed consent, to have good compliance, and to cooperate with follow-up visit.

Exclusion Criteria

1. Previously diagnosed with decompensated cirrhosis, and with portal vein and branch involvement or cancer embolus;

2. Pregnant or lactating, or plan to pregnant or give birth during the trial;

3. Persistent or active infection that are not controlled by treatment including but not limited to: active tuberculosis, non-negative HIV antibody, HBsAg positive and HBV DNA ≥LOQ, HCV ab positive and HCV DNA ≥LOQ;

4. Patients with imageological confirmed brain metastasis or brain metastasis history (except patients with stable disease within 3 months before screening and not require systemic glucorticoid therapy according to PI), pia meningeal disease, spinal cord compression;

5. Autoimmune disease or related symptoms, or previously suffered from autoimmune disease;

6. History of splenectomy or organ transplantation;

7. Prior treatment with Oncolytic virus (OV) (including but not be limited to T-VEC, T3011), gene therapy, cellular therapy or tumor vaccines;

8. Requires oral or intravenous therapy against herpes virus (including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs (eg. external use) are allowed;

9. Patients are scheduled to receive other therapy against malignant ascites (including but not limited to chemotherapy, target therapy, immunotherapy), and the best supportive treatment for malignant ascites is permitted (e.g., albumin supplements, etc.);

10. Patients with a known psychiatric disorder that would interfere with cooperation with the requirements of the trial;

11. History of narcotics (recreational use) and substance abuse (including alcohol) within 1 year prior to signing informed consent;

12. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody or any excipients for T3011;

13. History or evidence of high risk cardiovascular disease, including but not limited to:

• Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, QT interval corrected using the Fridericia formula (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female);
• Acute myocardial infarction, unstable angina pectoris, or stroke occurred within 6 months before the first administration of the experimental drug;
• Coronary angioplasty or stent implantation within 6 months prior to first administration of the experimental drug;
• Rating of heart function as defined by the New York Heart Association (NYHA) standards>grade II; Cardiac valve abnormalities recorded by echocardiography (≥ grade 2). Note: Subjects with grade 1 cardiac valve abnormalities (such as mild regurgitation/stenosis) were admitted, but subjects with moderate valve thickening were excluded;
• Left ventricular ejection fraction (LVEF) < the center lower limit. If no lower limit existed, LVEF<50%;
• Poor blood pressure control after antihypertensive treatment (i.e. systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);

14. History of another malignant tumor, except the following:

• Undergo potentially curative therapy and for ≥5 years prior to the first dose of study treatment and no malignancies with known active disease and low potential recurrence risk;
• Adequately treated non-melanoma skin cancer or lentigo with no evidence of malignancy;
• Adequately treated carcinoma in situ without evidence of disease;

15. Received live and attenuated vaccines within 4 weeks prior to initiation of study treatment, or plan to be vaccined during the study;

16. Previous history of immunotherapy induced non-infectious pneumonitis/ interstitial lung disease (including but not limited to ≥3 grade irAE) or intolerance to immunotherapy (including but not limited to anti-PD-(L)1 monoclonal Ab), except endocrine-related irAE that can be stably controlled by hormone replacement therapy;

17. Unexplained >38.5℃ fever (except for tumor induced fever judged by PI) occurs during the screening period, baseline period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or patient's efficacy evaluation;

18. Any condition that PI considered may confuse the trial results, interfere with the participant's participation in the trial, or is not in the participant's best interest to participate in the trial, or a history of treatment or laboratory abnormalities, or other ineligibility for enrollment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

West China Hospital

OTHER

Sponsor Role: lead

Responsible Party

Meng Qiu

Prof.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Site Status: RECRUITING

Countries

China

Central Contacts

Meng Qiu, MD

Role: CONTACT

qiumeng33@hotmail.com

028-85423203

Facility Contacts

Meng Qiu, MD

Role: primary

qiumeng33@hotmail.com

028-85423203

Other Identifiers

MVR-T3011-ES-EC61-MA

Identifier Type: -

Identifier Source: org_study_id